Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older

Sammy Saab, Sarah H. Park, Masashi Mizokami, Masao Omata, Alessandra Mangia, Ed Eggleton, Yanni Zhu, Steven J. Knox, Phil Pang, Mani Subramanian, Kris Kowdley, Nezam H. Afdhal

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Elderly subjects have been historically underrepresented in clinical trials involving antiviral hepatitis C therapies. The aim of this analysis was to retrospectively evaluate the safety and efficacy of ledipasvir/sofosbuvir (LDV/SOF) by age groups of

Original languageEnglish
JournalHepatology
DOIs
Publication statusAccepted/In press - 2016

Fingerprint

Hepatitis C
Antiviral Agents
Age Groups
Genotype
Clinical Trials
Safety
Therapeutics
sofosbuvir drug combination ledipasvir

ASJC Scopus subject areas

  • Hepatology

Cite this

Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. / Saab, Sammy; Park, Sarah H.; Mizokami, Masashi; Omata, Masao; Mangia, Alessandra; Eggleton, Ed; Zhu, Yanni; Knox, Steven J.; Pang, Phil; Subramanian, Mani; Kowdley, Kris; Afdhal, Nezam H.

In: Hepatology, 2016.

Research output: Contribution to journalArticle

Saab, S, Park, SH, Mizokami, M, Omata, M, Mangia, A, Eggleton, E, Zhu, Y, Knox, SJ, Pang, P, Subramanian, M, Kowdley, K & Afdhal, NH 2016, 'Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older', Hepatology. https://doi.org/10.1002/hep.28425
Saab, Sammy ; Park, Sarah H. ; Mizokami, Masashi ; Omata, Masao ; Mangia, Alessandra ; Eggleton, Ed ; Zhu, Yanni ; Knox, Steven J. ; Pang, Phil ; Subramanian, Mani ; Kowdley, Kris ; Afdhal, Nezam H. / Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. In: Hepatology. 2016.
@article{b9eadfefe4634707b19a7a6b65404f48,
title = "Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older",
abstract = "Elderly subjects have been historically underrepresented in clinical trials involving antiviral hepatitis C therapies. The aim of this analysis was to retrospectively evaluate the safety and efficacy of ledipasvir/sofosbuvir (LDV/SOF) by age groups of",
author = "Sammy Saab and Park, {Sarah H.} and Masashi Mizokami and Masao Omata and Alessandra Mangia and Ed Eggleton and Yanni Zhu and Knox, {Steven J.} and Phil Pang and Mani Subramanian and Kris Kowdley and Afdhal, {Nezam H.}",
year = "2016",
doi = "10.1002/hep.28425",
language = "English",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older

AU - Saab, Sammy

AU - Park, Sarah H.

AU - Mizokami, Masashi

AU - Omata, Masao

AU - Mangia, Alessandra

AU - Eggleton, Ed

AU - Zhu, Yanni

AU - Knox, Steven J.

AU - Pang, Phil

AU - Subramanian, Mani

AU - Kowdley, Kris

AU - Afdhal, Nezam H.

PY - 2016

Y1 - 2016

N2 - Elderly subjects have been historically underrepresented in clinical trials involving antiviral hepatitis C therapies. The aim of this analysis was to retrospectively evaluate the safety and efficacy of ledipasvir/sofosbuvir (LDV/SOF) by age groups of

AB - Elderly subjects have been historically underrepresented in clinical trials involving antiviral hepatitis C therapies. The aim of this analysis was to retrospectively evaluate the safety and efficacy of ledipasvir/sofosbuvir (LDV/SOF) by age groups of

UR - http://www.scopus.com/inward/record.url?scp=84959235497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959235497&partnerID=8YFLogxK

U2 - 10.1002/hep.28425

DO - 10.1002/hep.28425

M3 - Article

C2 - 26704693

AN - SCOPUS:84959235497

JO - Hepatology

JF - Hepatology

SN - 0270-9139

ER -